Our paper on the socio-economic consequences of #cushing 's syndrome has been accepted in JCEM!
Hope it'll be of value to patients and specialists.
See🧵below for study summary
https://t.co/3RwD2wyz83
@EndoSocJournals @EsbenSonder @HepatoEpi
@DDEA_Denmark 6/ Thanks to Per Løgstrup Poulsen @EsbenSonder @OlafDekkers Mark Gurnell, Conall Dennedy, Karin Hjorthaug and others for suggestions, inputs, assistance, etc in refining proposal and for future collaboration.
✨ #DDEA grants 33.9M DKK for research in diabetes, metabolism and endocrinology ✨
30 early-career and 7 visiting researchers will advance knowledge in diabetes, obesity, osteoporosis, and hormone-related fields.
🔗 Read the full press release here: https://t.co/nwqlLGLepm
We report detailed human studies to show that a substantial proportion of normotensive people exhibit phenotypic signatures of primary aldosteronism -providing mechanistic implications for the pathogenesis and treatment of hypertension @JeniferBrown
https://t.co/eOsWiCg6wD
Patients with #Cushing syndrome suffer significant socioeconomic consequences both prior and after diagnosis. @AEbbehoj presenting on this important topic at #ECE2023
The BMJ wants to publish the gold not the mould, the frankincense not the makes-no-sense, and the myrrh not the urrgghh.
This list of 12 statistical issues routinely encountered during peer review aims to help authors of future submissions #ChristmasBMJ
https://t.co/ePYzagXJzL
Honoured to work with collaborators in Chongqing on a study of Adrenal Tumors in an Unselected Screening Population. @AnnalsofIM 1.4% of 25356 people had adrenal tumors; 69% were non-functioning (in all age brackets), 12% had #PrimaryAldosteronism.
https://t.co/Q4FUZg1nOD
@IrinaBancos@LMFendo@AnandVaidya17 @tobi_else Only that
1) bladder-PGL incidence didnt change (as seen for pheo & other PGLs due to 📈incidental findings) ➡️ suggests IMO that lots of patients go undiagnosed.
2) Genetic work-up was -ahem- not optimal (~50%) ➡️ a missed opportunity to find and treat affected families.
United multicenter effort between #pheo experts to improve management of bladder #paraganglioma: Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results from a Multi-center Study https://t.co/5DzkQGBFOg @MayoClinicEndo@PheoPara@ParaTroupers1
Pretty stoked that @EndoSocJournals just published a commentary on our study. Authored by none other than CS experts Susan M Webb & @E_Valassi 😮🤯
https://t.co/BaHu16mEUq
14/ Study limitations:
No access to clinical data from medical records (recurrence, disease severity, etc).
Validation sample did not indicate that we included any patients with MACS/subclinical CS but one can never be certain.